title: Use of statins and outcome of BCG treatment for bladder cancer.
authors.forename: Paul
authors.initials: P
authors.lastname: Hoffmann
authors.forename: Thierry
authors.initials: T
authors.lastname: Roumeguère
authors.forename: Claude
authors.initials: C
authors.lastname: Schulman
authors.forename: Roland
authors.initials: R
authors.lastname: van Velthoven
mesh_terms: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D002278:Carcinoma in Situ / Q000628:therapy*; D002784:Cholesterol / Q000097:blood; D016207:Cytokines / Q000187:drug effects / Q000652:urine; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D012189:Retrospective Studies; D018417:Th1 Cells / Q000187:drug effects; D018418:Th2 Cells / Q000187:drug effects; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol